|
Infection caused by Helicobacter pylori
|
0.100 |
Biomarker
|
disease |
BEFREE |
The patients were found to be CYP2C19 extensive metabolizers and negative for Helicobacter pylori infection.
|
28662503 |
2017 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial.
|
27107097 |
2016 |
|
Infection caused by Helicobacter pylori
|
0.100 |
Biomarker
|
disease |
BEFREE |
Logistic regression analysis showed that only CYP2C19*17 was associated with PUD (odds ratio additive model: 1.47 (95% confidence interval (CI) 1.12 to 1.92); P = 0.005; R(2) 16%), but not UGIB, independent of NSAID use or Helicobacter pylori infection.
|
23267857 |
2013 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
|
21118735 |
2010 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
|
19968574 |
2010 |
|
Infection caused by Helicobacter pylori
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prospective study was designed to clarify the impact of CYP2C19 on quadruple therapies and survey the efficacies of rabeprazole-based quadruple therapy for Helicobacter pylori infection after failure of standard triple therapies.
|
20633187 |
2010 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether or not CYP2C19 genotype status is associated with cure rate for Helicobacter pylori infection in patients with cirrhosis and peptic ulcer, achieved with 2 weeks of triple therapy with rabeprazole, amoxicillin and clarithromycin.
|
20457439 |
2010 |
|
Infection caused by Helicobacter pylori
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
|
20376628 |
2010 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies with CYP2C19 slow metabolizers have shown that the combination of a proton pump inhibitor (PPI) plus amoxicillin (dual therapy) can reliably cure more than 90% of Helicobacter pylori infections.
|
20195646 |
2010 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
|
18823430 |
2009 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 polymorphisms have been inconsistently reported to associate with the efficacy of proton pump inhibitor (PPI)-based triple therapies for eradicating Helicobacter pylori infection.
|
19166419 |
2008 |
|
Infection caused by Helicobacter pylori
|
0.100 |
Biomarker
|
disease |
BEFREE |
These CYP2C19 genotypic differences in pharmacokinetics and pharmacodynamics of PPIs influence the healing and eradication rates for the gastro-esophageal reflux disease and Helicobacter pylori infection by PPI-based regimens.
|
17924835 |
2007 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection?
|
16863548 |
2006 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
|
15710002 |
2005 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
|
15976989 |
2005 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
|
16268979 |
2005 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These CYP2C19 genotype-dependent differences in pharmacokinetics and pharmacodynamics of PPIs influence the cure rates for the gastro-esophageal reflux disease and H. pylori infection by PPI-based therapies.
|
15988117 |
2005 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These CYP2C19 genotype-dependent differences in pharmacokinetics and pharmacodynamics of PPIs are reflected in the cure rates for gastroesophageal reflux disease and Helicobacter pylori infection with PPI-based therapies.
|
15016609 |
2004 |
|
Infection caused by Helicobacter pylori
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
|
14615467 |
2003 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
|
12544691 |
2003 |
|
Infection caused by Helicobacter pylori
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pharmacokinetic and pharmacodynamic data suggest that CYP2C19 poor metabolizers might be subject to advantageous conditions, especially after day 4, for treating H. pylori infection with rabeprazole.
|
12820812 |
2003 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
|
12534411 |
2003 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
|
12121503 |
2002 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We intended to determine a cure rate for Helicobacter pylori infection by dual rabeprazole/amoxicillin therapy in relation to CYP2C19 genotype status prospectively.
|
11434512 |
2001 |
|
Infection caused by Helicobacter pylori
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
|
11446878 |
2001 |